

Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

1 Completion of multi-dose COVID-19 vaccines and the associated factors among adolescents 2 and adults in two urban informal settlements in Nairobi, Kenya

3 Authors

4 Maurine Ng'oda¹, Jonathan Izudi², Collins Otieno¹, Daniel Mwanga², Richard E. Sanya¹,
5 Abdhalah Ziraba¹

6 Affiliations

7 ¹Emerging and Re-Emerging Infectious Diseases Unit, African Population and Health Research
8 Center, Nairobi, Kenya.

9 ²Data Science and Evaluation, African Population and Health Research Center, Nairobi, Kenya.

10

11

12 Corresponding author

13 Maurine Ng'oda*

14 African Population and Health Research Center, Nairobi

15 Email: mngoda@aphrc.org

16 Phone: +254724137389

Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

17 ABSTRACT

18 Completion of vaccine doses is essential for robust immunity and long-term protection
19 against specific diseases. This study aimed to investigate factors associated with the completion of
20 multi-dose COVID-19 vaccines (MDV) among adolescents and adults in two informal urban
21 settlements in Nairobi, Kenya. We analyzed data from the Kenya Multisite Integrated
22 Serosurveillance (KEMIS) project. We defined completion of MDV as receiving an additional
23 COVID-19 vaccine dose between weeks 6 and 8 following the first COVID-19 vaccination shot.
24 We applied the modified Poisson regression model with robust standard errors to determine the
25 factors that were independently associated with the completion of MDV. We analyzed data from
26 402 individuals aged 14-90 years and found that the completion rate for MDV was 85.3%. In the
27 adjusted analysis, participants aged ≥ 60 years (adjusted prevalence risk ratio [aPR] 1.30, 95%
28 confidence interval [CI] 1.05-1.60) and those who recommended the COVID-19 vaccine to others
29 (aPR 1.40, 95% CI 1.00-1.96) were significantly more likely to complete MDV. Individuals aged
30 25-59 years (aPR 1.22, 95% CI 0.99-1.50), those who perceived themselves as being at risk for
31 COVID-19 (aPR 1.09, 95% CI 0.99-1.19), and those who had access to healthcare during the
32 pandemic tended to have a higher completion of MDV. Overall, the MDV completion rate is
33 relatively high, however, public health interventions should endeavor to target those being left
34 behind such as younger individuals and those hesitant about vaccination.

35 **KEYWORDS:** Vaccines, COVID-19, multiple doses, informal settings.

36

Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

37 BACKGROUND

38 The COVID-19 pandemic posed unprecedented challenges to global public health, with
39 vaccination emerging as one of the most effective tools to mitigate transmission and reduce severe
40 outcomes such as hospitalization and mortality.¹ By August 12, 2024, 13.72 billion doses of
41 COVID-19 vaccine had been administered globally. However, Africa had received the least
42 number of doses (874.76 million),² revealing significant gaps in both vaccine access and uptake.^{3,4}

43 In Kenya, the most commonly used COVID-19 vaccines included Oxford/AstraZeneca,
44 Moderna, and Pfizer and each requires multiple doses to ensure complete immunization.⁵ The
45 completion of multi-dose vaccine regimens is critical for eliciting stronger immunity and longer-
46 term protection against severe COVID-19. The second dose significantly enhances the immune
47 response, boosting the efficacy to over 90% in preventing severe disease.⁶ Failure to complete
48 multi-dose regimens undermines this protection and potentially leads to vaccine failure, greater
49 risks for infection, and reduced overall effectiveness of immunization programs including
50 increased susceptibility to COVID-19 variants and reduced community-level immunity.⁷

51 Disparities in the completion of multi-dose vaccines for COVID-19 (MDV) exist,
52 particularly in low-income and marginalized populations such as urban informal settlements.⁸
53 Urban informal settlements are often characterized by overcrowding, inadequate healthcare
54 infrastructure, and limited access to essential services. In Kenya, an estimated 60% of the residents
55 in Nairobi City reside in informal settlements. The overall COVID-19 vaccine uptake among this
56 population is around 34%⁹ but the completion of MDV is understudied. Understanding the
57 completion of MDV is crucial for developing targeted interventions that improve COVID-19
58 vaccine uptake in such settings. We investigated the prevalence of completion of MDV and the

Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

59 associated factors among adolescents and adults in two large urban informal settlements in
60 Nairobi, Kenya.

61

62 **MATERIALS AND METHODS**

63 **Study setting**

64 Data used in this paper comes from the Kenya Multisite Integrated Serosurveillance
65 (KEMIS) for COVID-19 and Other Pathogens Project. The KEMIS Project was jointly
66 implemented by the African Population and Health Research Center (APHRC), the Kenya Medical
67 Research Institute Wellcome Trust Research Programme, and the Centers for Disease Control and
68 Prevention (CDC). The project aimed to estimate the sero-prevalence of SARS-CoV-2 antibodies
69 in the general population. It involved serosurveys conducted among residents of Kilifi, Nairobi,
70 and Manyatta Health and Demographic Surveillance Systems (HDSS). The details of HDSS have
71 been previously discussed.⁹ The analysis in this paper comes from the Nairobi site. The Nairobi
72 Urban HDSS (NUHDSS) is established in Nairobi City County, and has consistently tracked a
73 population of approximately 90,000 people each year spread across 30,000 households in two slum
74 areas of Korogocho and Viwandani.¹⁰

75 **Study design and eligibility**

76 Four cross-sectional sero-surveys were conducted between October 2020 and June 2024
77 on a random age-stratified sample of 850 NUHDSS residents totaling 3,400 observations. These
78 samples consisted of 50 people from each 5-year age group between 15 and 64 years, 50 people
79 aged 65 and above, and 100 children from each 5-year age group between 0 and 14 years. This

Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

80 resulted in 300 participants under 15 years old sufficient to estimate a 1% outcome measure rate
81 with a 2% margin of error. For the 15-64 age group, 500 participants were deemed adequate to
82 estimate an outcome rate of 3-5% within a 5% margin of error. The survey excluded individuals
83 with bleeding disorders and other medical contraindications for venipuncture or capillary blood
84 sample collection. Data was collected using structured questionnaires and laboratory analysis of
85 blood samples for COVID-19 antibodies. The questionnaire captured sociodemographic
86 information, information on likely exposure to SARS-Cov-2, and clinical information such as
87 COVID-19 symptoms, childhood immunization, death of household members, and vaccination
88 status. Vaccination status was verified using the vaccination certificate or text message
89 confirmation from the national COVID-19 registry. Other information collected included access
90 to health services during the pandemic and loss of income during COVID-19.

91

92 Measurements and variables

93 The present study utilized data from the second and third survey rounds of the survey since
94 the first round of the survey took place before the COVID-19 vaccine rollout in the country and
95 the fourth round of the survey did not include key variables that were considered for the current
96 analysis. We considered observations for individuals who were eligible for COVID-19 vaccination
97 and who had received the first dose of MDV, namely AstraZeneca, Moderna, Pfizer, and
98 Sinopharm. We excluded records for the following individuals: those ineligible for the COVID-
99 19 vaccine based on age, who never received any COVID-19 vaccination, who never knew the
100 vaccine they had received at first vaccination, and those who had missing vaccination information.

Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

101 The primary outcome variable of interest was completion of MDV measured as a binary
102 outcome and defined as the receipt of an additional dose of a COVID-19 vaccine between weeks
103 6 and 8 following the first dose of an MDV. The independent variables included age measured as
104 the number of years lived and categorized as 14–24, 25–59, and ≥ 60 years to respectively denote
105 adolescents and young people, middle-aged persons, and older persons; sex (male vs. female);
106 religion measures as None, Muslim, Christians, and Others; education level was measured as
107 none, primary, secondary, and post-secondary; exposure to a suspected COVID-19 case was
108 measured as no, yes, probable, and not reported; access to healthcare during the COVID-19
109 pandemic was measured on a binary scale as yes or no; and perceived risk of COVID-19 infection
110 was measured as no risk vs. at risk. Additionally, we assessed vaccine whether the participants
111 were willing to recommend COVID-19 vaccination to others and whether they had any household
112 member who had died from COVID-19.

113 **Statistical analysis**

114 We summarized categorical variables as frequencies and proportions. Numerical variables
115 were summarized using the mean and standard deviation as they were normally distributed. The
116 Chi-square test was used to examine differences in MDV completion by the covariates at a 0.15
117 significance level in the bivariate analysis. We used the modified (robust) Poisson regression
118 model to determine the factors independently associated with MDV completion adjusting for both
119 clinically and socially relevant variables from the literature, statistically significant variables at the
120 bivariate analysis, and robust standard errors as recommended by Cameron and Trivedi. We report
121 both the unadjusted and adjusted prevalence risk ratios (PR) along with the 95% confidence
122 intervals (CIs). Variables with $p < 0.05$ were considered statistically significant in the multivariable
123 modified Poisson regression analysis.

Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

124

125 **Ethical considerations**

126 The KEMIS project obtained ethical approval from the Kenya Medical Research Institute
127 Scientific and Ethics Review Unit (Reference no. KEMRI/SERU/ CGMR-C/203/4085), The
128 National Commission for Science, Technology and Innovation (License no.
129 NACOSTI/P/21/13771), the Oxford Tropical Research Ethics Committee (Reference no. 44–20),
130 and the London School of Hygiene and Tropical Medicine Research Ethics Committee (Reference
131 no. 26950). Written parental/guardian consent was obtained for participants aged <18 years,
132 accompanied by written assent for children aged 13 to 17 years.


133

134 **RESULTS**

135 **Study profile**

136 We considered data from 1,701 participants and excluded 1,295 that did not meet the
137 eligibility criteria. Overall, we analyzed 402 participants of whom 343 (85.0%) completed MDV
138 as shown in Figure 1.

Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings



139

140 Figure 1. Study profile based on eligibility criteria.

141

142 General characteristics of the participants

143 We present the general characteristics of the participants in Table 1. Of the 402 participants,
144 262 (65.2%) were from Viwandani study site, 264 (65.7%) were male, 254 (63.2%) were aged
145 25-59 years and the overall mean age was 48.5 ± 15.7 332 (80.1%) participants had no known
146 contact with confirmed/suspected COVID-19 cases, 260 (64.7%) perceived themselves as being
147 at risk for infection, and 361 (89.8%) lacked access to healthcare during the pandemic.

148

149

150

151

Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

152
153
154
155
156
157
158
159
160
161

Table 1. General characteristics of participants who received multi-dose COVID-19 vaccine

| Variables | Level | All (n=402) |
|-----------------------------------------|----------------|--------------------|
| Study site | Korogocho | 140 (34.8) |
| | Viwandani | 262 (65.2) |
| Survey rounds | Round 2 | 172 (42.8) |
| | Round 3 | 230 (57.2) |
| Age group (years) | 14-24 | 43 (10.7) |
| | 25-59 | 254 (63.2) |
| | ≥60 | 105 (26.1) |
| | mean (SD) | 48.53 (15.71) |
| Sex | Female | 138 (34.3) |
| | Male | 264 (65.7) |
| Level of education | None | 16 (4.0) |
| | Primary | 169 (42.0) |
| | Secondary | 179 (44.5) |
| | Post-secondary | 38 (9.5) |
| Religion | None | 9 (2.2) |
| | Muslim | 13 (3.2) |
| | Christians | 270 (67.2) |
| | Others | 110 (27.4) |
| Ever exposed to suspected COVID-19 case | No | 332 (80.1) |

Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

| | | |
|-------------------------------------------------------|--------------|------------|
| | Yes | 36 (9.0) |
| | Probable | 30 (7.5) |
| | Not reported | 14 (3.5) |
| Had access to healthcare during the COVID-19 pandemic | No | 361 (89.8) |
| | Yes | 35 (8.7) |
| | Not reported | 6 (1.5) |
| Perceived risk of infection with COVID-19 | No risk | 142 (35.3) |
| | At risk | 260 (64.7) |
| History of the household member who died of COVID-19 | No | 370 (92.0) |
| | Yes | 30 (7.5) |
| | Do not know | 2 (0.5) |
| Would recommend the COVID-19 vaccine to others | No | 19 (4.7) |
| | Yes | 383 (95.3) |

162

163

164

165 **Type and timing of receipt of multi-dose COVID-19 vaccine (MDV)**

166 Table 2 summarizes the types and timing of MDV at the first and second shots. At the first
167 shot, 266 (66.2%) participants received the AstraZeneca vaccine, 61 (15.2%) received Pfizer, 74
168 (18.4%) received Moderna, and 1 (0.2%) received the Sinopharm vaccine. At the second shot, the
169 number of participants that received the AstraZeneca vaccine dropped to 224 (55.7%), and that for
170 Pfizer and Moderna dropped to 59 (14.7%) and 56 (13.9%) respectively. One participant received
171 Sinopharm at the first and second shots. At the second shot, 59 (14.7%) participants did not return
172 for their COVID-19 vaccine. Overall, 343 (85.3%) participants completed their MDV in this study.

173

174

175

176

Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

177

178

179

180

181

182

183

184 **Table 2. Type and timing of receipt of multi-dose COVID-19 vaccine (MDV)**

| Variable | Level | Overall (n=402) |
|---------------------------------------------|----------------|-----------------|
| COVID-19 vaccine at the first shot | AstraZeneca | 266 (66.2) |
| | Pfizer | 61 (15.2) |
| | Moderna | 74 (18.4) |
| | Sinopharm | 1 (0.2) |
| COVID-19 vaccine at the second shot | AstraZeneca | 224 (55.7) |
| | Pfizer | 59 (14.7) |
| | J & J | 1 (0.2) |
| | Moderna | 56 (13.9) |
| | Sinopharm | 1 (0.2) |
| | Don't know | 2 (0.5) |
| Completed multi-dose COVID-19 vaccine (MDV) | Never returned | 59 (14.7) |
| | No | 59 (14.7) |
| | Yes | 343 (85.3) |

185

186 **Completion of MDV by the socio-demographic characteristics and other factors**

187 The completion of MDV varied across different sociodemographic characteristics and
188 other influencing factors as shown in Table 3. Completion rates were high across both study sites,
189 with 85.7% in Korogocho and 85.1% in Viwandani (p=0.871). Individuals aged ≥ 60 years had the

Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

190 highest completion rate at 91.4%, while those aged 14-24 had a lower completion rate at 69.8%
191 (p=0.003). The mean age of completers was significantly higher (50.14 years) compared to non-
192 completers (39.17 years, p<0.001). There were no significant differences in completion rates by
193 sex, with males and females completing at rates of 85.6% and 84.8%, respectively (p=0.825).
194 Educational level showed modest differences, with those having no education showing the highest
195 completion rate (93.8%), though this was not statistically significant (p=0.504). Religion was not
196 a significant factor, though Muslims reported a 100% completion rate compared to 86.7% among
197 Christians (p=0.102). The perceived risk of COVID-19 infection was marginally associated with
198 completion, as those perceiving themselves at risk had a higher completion rate (87.7%) compared
199 to those perceiving no risk (81.0%, p=0.069). Finally, willingness to recommend the COVID-19
200 vaccine was significantly associated with completion; 86.4% of those who would recommend the
201 vaccine completed MDV compared to 63.2% among those who would not recommend it
202 (p=0.005).

203

204

205

206

207

208

209

210

Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

211

212

213

214

215

216 **Table 3: Completion of MDV by the socio-demographic characteristics and other factors**

| Variables | Level | Completed MDV | | P-value |
|-----------------------------------------|----------------|---------------|---------------|---------|
| | | No (n=59) | Yes (n=343) | |
| Study site | Korogocho | 20 (14.3) | 120 (85.7) | 0.871 |
| | Viwandani | 39 (14.9) | 223 (85.1) | |
| Survey rounds | Round 2 | 26 (15.1) | 146 (84.9) | 0.829 |
| | Round 3 | 33 (14.3) | 197 (85.7) | |
| Age group (years) | 14-24 | 13 (30.2) | 30 (69.8) | 0.003 |
| | 25-59 | 37 (14.6) | 217 (85.4) | |
| | ≥60 | 9 (8.6) | 96 (91.4) | |
| | mean (SD) | 39.17 (15.73) | 50.14 (15.16) | |
| Sex | Female | 21 (15.2) | 117 (84.8) | 0.825 |
| | Male | 38 (14.4) | 226 (85.6) | |
| Level of education | None | 1 (6.3) | 15 (93.8) | 0.504 |
| | Primary | 22 (13.0) | 147 (87.0) | |
| | Secondary | 31 (17.3) | 148 (82.7) | |
| | Post-secondary | 5 (13.2) | 33 (86.8) | |
| Religion | None | 3 (33.3) | 6 (66.7) | 0.102 |
| | Muslim | 0 (0.0) | 13 (100.0) | |
| | Christians | 36 (13.3) | 234 (86.7) | |
| | Others | 20 (18.2) | 90 (81.8) | |
| Ever exposed to suspected COVID-19 case | No | 44 (13.7) | 278 (86.3) | 0.660 |
| | Yes | 7 (19.4) | 29 (80.6) | |
| | Probable | 6 (20.0) | 24 (80.0) | |
| | Not reported | 2 (14.3) | 12 (85.7) | |

Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

| | | | | |
|-------------------------------------------------------|--------------|-----------|------------|-------|
| Had access to healthcare during the COVID-19 pandemic | Yes | 3 (8.6) | 32 (91.4) | 0.562 |
| | No | 55 (15.2) | 306 (84.8) | |
| | Not reported | 1 (16.7) | 5 (83.3) | |
| Perceived risk of infection with COVID-19 | No risk | 27 (19.0) | 115 (81.0) | 0.069 |
| | At risk | 32 (12.3) | 228 (87.7) | |
| History of the household member who died of COVID-19 | No | 56 (15.1) | 314 (84.9) | 0.166 |
| | Yes | 2 (6.7) | 28 (93.3) | |
| | Do not know | 1 (50.0) | 1 (50.0) | |
| Would recommend the COVID-19 vaccine to others | Yes | 52 (13.6) | 331 (86.4) | 0.005 |
| | No | 7 (36.8) | 12 (63.2) | |

217

218

219 Factors associated with the completion of MDV at the unadjusted and adjusted analyses

220 In the unadjusted analysis, participants aged 25-59 years (PR 1.22, 95% CI 1.00-1.50) and
 221 ≥ 60 years (PR 1.31, 95% CI 1.07-1.61) were more likely to complete MDV compared to those
 222 aged 14-24 years. Being a male compared to a female was not associated with completion of MDV
 223 (PR 1.01, 95% CI 0.93-1.10). Education levels, namely primary (PR 0.93, 95% CI 0.81-1.07),
 224 secondary (PR 0.88, 95% CI 0.76-1.02), and post-secondary education (PR 0.93, 95% CI 0.78-
 225 1.11) showed no significant association with completion of MDV compared to no formal
 226 education. Participants who perceived themselves as being at risk for COVID-19 (PR 1.08, 95%
 227 CI 0.99-1.19) and those who would recommend the vaccine to others (PR 1.37, 95% CI 0.97-1.93)
 228 tended to have a higher likelihood of completion of MDV.

229 In the adjusted analysis, participants aged ≥ 60 years (aPR 1.30, 95% CI 1.05-1.60) and
 230 those who would recommend the COVID-19 vaccine to others (aPR 1.40, 95% CI 1.00-1.96) were
 231 more likely to complete MDV. We found a borderline statistically significant association between

Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

232 being aged 25-59 years compared to 14-24 years (aPR 1.22, 95% CI 0.99 - 1.50), access to
 233 healthcare during the COVID-19 pandemic (aPR 1.09, 95% CI 0.97 - 1.22), and perceived risk of
 234 COVID-19 (aPR 1.09, 95% CI 0.99 - 1.19).

235

236

237 **Table 4. Factors associated with the completion of MDV**

| | | Modified Poisson Regression analysis | |
|-------------------------------------------------------|----------------|---------------------------------------------|--------------------------|
| | | Unadjusted analysis | Adjusted analysis |
| Variables | Level | PR (95% CI) | aPR (95% CI) |
| Site name | Korogocho | 1 | 1 |
| | Viwandani | 0.99 (0.91 - 1.08) | 1.02 (0.93 - 1.11) |
| Age group (years) | 14-24 | 1 | 1 |
| | 25-59 | 1.22* (1.00-1.50) | 1.22 (0.99 - 1.50) |
| | ≥60 | 1.31*** (1.07-1.61) | 1.30** (1.05 - 1.60) |
| Sex | Female | 1 | 1 |
| | Male | 1.01 (0.93 - 1.10) | 1.02 (0.93 - 1.11) |
| Level of education | None | 1 | 1 |
| | Primary | 0.93 (0.81 - 1.07) | 0.98 (0.85 - 1.13) |
| | Secondary | 0.88* (0.76 - 1.02) | 0.95 (0.82 - 1.10) |
| | Post-secondary | 0.93 (0.78 - 1.11) | 1.01 (0.83 - 1.23) |
| Ever exposed to suspected COVID-19 case | No | 1 | 1 |
| | Yes | 0.93 (0.79 - 1.10) | 0.90 (0.76 - 1.07) |
| | Probable | 0.93 (0.77 - 1.11) | 0.93 (0.78 - 1.11) |
| | Not reported | 0.99 (0.80 - 1.24) | 0.98 (0.81 - 1.18) |
| Had access to healthcare during the COVID-19 pandemic | No | 1 | 1 |

Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

| | | | |
|------------------------------------------------|--------------|---------------------|----------------------|
| | Yes | 1.08 (0.97 - 1.20) | 1.09 (0.97 - 1.22) |
| | Not reported | 0.98 (0.69 - 1.41) | 1.01 (0.68 - 1.51) |
| Perceived risk of infection with COVID-19 | No risk | 1 | 1 |
| | At risk | 1.08 (0.99 - 1.19) | 1.09 (0.99 - 1.19) |
| Would recommend the COVID-19 vaccine to others | No | 1 | 1 |
| | Yes | 1.37* (0.97 - 1.93) | 1.40** (1.00 - 1.96) |

238 **Note:** Exponentiated coefficients are the prevalence risk ratios at a 5% significance level; 95%
 239 confidence intervals in brackets: * p<0.05, ** p<0.01, *** p<0.001; PR: Unadjusted prevalence
 240 risk ratio; aPR: Adjusted prevalence risk ratio. Analysis adjusted for the survey round.

241

242 DISCUSSION

243 We assessed the factors associated with the completion of MDV in Nairobi's informal
 244 settlements. Our findings indicate that 8 in every 10 individuals in the informal settlements who
 245 ever received a COVID-19 vaccine completed their MDV. Completion of MDV is more likely for
 246 middle-aged (25-59 years) and older adults (60+ years) individuals compared to younger
 247 participants (14-24 years) and among those reporting willingness to recommend COVID-19
 248 vaccination to others. Furthermore, individuals who perceived themselves at risk for COVID-19
 249 and those who had access to health services during the pandemic tended to have a higher likelihood
 250 of completing their MDV.

251 Age has been shown in previous studies to be a significant determinant of vaccine uptake
 252 ^{11,12} and our findings align with this evidence. The high completion rate of MDV among middle-
 253 aged individuals, who comprise the majority of the working population, may have been likely
 254 influenced by the COVID-19 restrictions that largely affected city employees. Across urban areas,

Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

255 including Nairobi, several employers mandated COVID-19 vaccination as a requirement for
256 continued employment, especially in sectors involving close contact with others, such as
257 hospitality, transport, and retail.^{13,14} These mandates might have incentivized middle-aged workers
258 to complete their MDV regimens in order to retain their jobs and avoid financial instability
259 Compared to younger persons, middle-aged and older individuals might have prioritized
260 vaccination in order to reduce the risk of transmission of SARS-COV-2 (the virus causing COVID-
261 19) at the household level. Diesel and colleagues (2021) argued that older adults are more likely
262 to complete their COVID-19 vaccine regimens due to a greater awareness of the health risks
263 associated with COVID-19.¹⁵ One study indicated that older adults prioritize vaccination due to
264 their higher perceived risk of severe outcomes associated with COVID-19.¹⁶

265 We found that participants who would recommend the COVID-19 vaccine to others are
266 more likely to complete their MDV compared to those who would not recommend the COVID-19
267 vaccine to others. This finding highlights the critical role of vaccine confidence in shaping health
268 behavior. Vaccine-non-hesitant individuals often have a higher level of trust in the safety and
269 efficacy of vaccines, which motivates them to get vaccinated and advocate for others to equally
270 get vaccinated.¹⁷ This positive attitude toward vaccination likely translates into greater adherence
271 to completing the full vaccine schedule since such individuals likely appreciate the benefits of
272 vaccination. Contrastingly, vaccine-hesitant individuals may harbour doubts about vaccine safety
273 or question its necessity and hence are less likely to commit to completing the multi-dose
274 regimens.¹⁷ This finding emphasizes the importance of addressing vaccine hesitancy through
275 public health messaging and community engagement, particularly in settings like informal urban
276 settlements where misinformation and distrust are prevalent.

Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

277 Individuals with a perceived risk of COVID-19 infection showed a marginally higher
278 tendency to complete their MDV. We argue that feeling at risk of COVID-19 infection, by itself,
279 may not sufficiently motivate an individual to adhere to vaccination schedules but rather other
280 factors such as the perceived benefits of full vaccination, easy access to vaccines, trust in the health
281 system, and influences from the social networks.^{18–20} Even though some individuals might
282 acknowledge that they are at risk for COVID-19, they may still hesitate to get vaccinated due to
283 concerns about vaccine side effects, doubts about its effectiveness, or general mistrust of health
284 interventions.^{20,21} Moreover, the lack of significant findings might suggest that people often need
285 more than just a sense of risk to act. Public health theories such as the Health Belief Model
286 highlight that while perceived risk can increase awareness, it often takes "cues to action" to trigger
287 a response.²² These cues could include reminders from health professionals, public health
288 campaigns, or healthy public policies such as vaccine mandates.

289 There are also other important dynamics at play such as vaccine fatigue.²³ Some people
290 might have been eager to get their initial dose but then become reluctant to receive subsequent
291 doses due to misinformation or concerns after the first vaccination. This highlights that even when
292 perceived risk is high, other competing factors may prevent people from completing their
293 vaccination schedule.

294 Structural barriers such as limited access to vaccines, financial constraints, or the inability
295 to take time off work also negatively affect people in urban slum environments regarding
296 vaccination uptake. In urban informal settlements, basic needs such as food or income are
297 prioritized over long-term health needs such as vaccination. Overall, public health strategies that

Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

298 focus exclusively on raising awareness of the risks associated with COVID-19 may not be effective
299 in improving vaccine completion.

300 This study has numerous strengths and some limitations to note. The use of a modified
301 Poisson regression analysis prevented the overestimation of associations between the independent
302 variables and the outcome, hence providing better estimates. The study was conducted in only two
303 informal settlements in Nairobi so the findings may not generalize to other urban slums. Missing
304 data, particularly from participants who were unaware of the type of vaccine they had received at
305 the first shot might have led to either under or overestimation of the completion of MDV. Despite
306 these limitations, the study provides credible findings about the completion of MDV in urban
307 informal settlements where access to healthcare remains problematic and individuals are at a
308 higher risk for diseases, complications, and mortality.

309 We conclude that the completion rate for MDV is relatively high. However, to further
310 enhance vaccination coverage, public health interventions should focus on targeted education,
311 emphasizing the importance of completing the full vaccination schedule. These efforts should
312 prioritize younger individuals and those displaying vaccine hesitancy, ensuring that critical gaps
313 in coverage are addressed and sustained immunity is achieved within the population.

314

315 **ACKNOWLEDGEMENTS**

316 This work is part of the African Population and Health Research Center's commitment to
317 advancing public health research in Africa, particularly in understanding and addressing health
318 challenges within underserved communities. We are deeply grateful to our collaborators, the

Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

319 KEMRI Wellcome Trust Research Program and the Africa CDC, for their invaluable partnership
320 in the KEMIS project. We also wish to thank the dedicated field data collectors and the community
321 members who participated in the study, whose contributions were essential to this work. APHRC
322 had no role in the study's conceptualization, design, conduct, data analysis, or the decision to
323 submit and publish the manuscript. The contents are solely the responsibility of the authors.

324

325 **FUNDING**

326 The KEMIS project was supported by funding from the Bill and Melinda Gates Foundation
327 (Ref No. C1055). The funder did not participate in the conceptualization, design, conduct, data
328 analysis, or the decision to submit and publish this manuscript.

329

330 **CONFLICT OF INTEREST**

331 Authors declare no competing interests.

332

333 **AUTHOR DETAILS**

334 Maurine Ng'oda; African Population and Health Research Center, Nairobi, Kenya;
335 Maurinekn2012@gmail.com / mngoda@aphrc.org.

336 Jonathan Izudi; African Population and Health Research Center, Nairobi Kenya;
337 jizudi@aphrc.org.

338 Collins Otieno; African Population and Health Research Center, Nairobi, Kenya;
339 otienoc292@gmail.com.

340 Daniel Mwanga; African Population and Health Research Center, Nairobi, Kenya:
341 dmwanga@aphrc.org.

Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

342 Richard E. Sanya; African Population and Health Research Center, Nairobi, Kenya;

343 rsanya@aphrc.org.

344 Abdhahah Ziraba; African Population and Health Research Center, Nairobi, Kenya;

345 aziraba@aprc.org.

346

347 **DATA AVAILABILITY**

348 All the data used in this manuscript are archived at

349 <https://microdataportal.aphrc.org/index.php/catalog/central> and can be formally requested for

350 through the institutional guidelines.

351

352 **AUTHOR DECLARATION**

353 All authors have seen and approved this manuscript.

354

Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

REFERENCES

1. Kim D, Lee YJ. Vaccination strategies and transmission of COVID-19: Evidence across advanced countries. *J Health Econ*. 2022;82(January):102589. doi:10.1016/j.jhealeco.2022.102589
2. Our World in Data. Total COVID-19 vaccine doses administered.
3. Doshi RH, Nsasiirwe S, Dahlke M, et al. COVID-19 Vaccination Coverage — World Health Organization African Region, 2021–2023. *MMWR Morb Mortal Wkly Rep*. 2024;73(14):307-311. doi:10.15585/mmwr.mm7314a3
4. Jacobs C, Musonda NC, Tembo D, et al. Gender disparities and associated factors to intention to getting a second dose of COVID-19 AstraZeneca vaccine among adult populations in selected facilities of Lusaka, Zambia. *PLOS Glob Public Heal*. 2022;2(7):e0000265. doi:10.1371/journal.pgph.0000265
5. Solante R, Alvarez-Moreno C, Burhan E, et al. Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic. *Expert Rev Vaccines*. 2023;22(1):1-16. doi:10.1080/14760584.2023.2143347
6. García-Montero C, Fraile-Martínez O, Bravo C, et al. An updated review of sars-cov-2 vaccines and the importance of effective vaccination programs in pandemic times. *Vaccines*. 2021;9(5):1-22. doi:10.3390/vaccines9050433
7. Crutcher M, Seidler PM. Maximizing completion of the two-dose COVID-19 vaccine series with aid from infographics. *Vaccines*. 2021;9(11). doi:10.3390/vaccines9111229
8. Ekezie W, Awwad S, Krauchenberg A, et al. Access to Vaccination among Disadvantaged, Isolated and Difficult-to-Reach Communities in the WHO European Region: A Systematic Review. *Vaccines*. 2022;10(7). doi:10.3390/vaccines10071038
9. Kagucia EW, Ziraba AK, Nyagwange J, et al. SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February–December 2022. *Influenza Other Respi Viruses*. 2023;17(9):1-11. doi:10.1111/irv.13173
10. Beguy D, Elung'ata P, Mberu B, et al. Health & Demographic Surveillance System Profile: The Nairobi Urban Health and Demographic Surveillance System (NUHDSS). *Int J Epidemiol*. 2015;44(2):462-471. doi:10.1093/ije/dyu251
11. Amoah JO, Abraham SA, Adongo CA, et al. Determinants of COVID-19 vaccine uptake: evidence from a vulnerable global South setting. *BMC Res Notes*. 2024;17(1):1-7. doi:10.1186/s13104-024-06736-5
12. Pijpers J, van Roon A, van Roekel C, et al. Determinants of COVID-19 Vaccine Uptake in The Netherlands: A Nationwide Registry-Based Study. *Vaccines*. 2023;11(9):1409. doi:10.3390/VACCINES11091409/S1

Completion of multi-dose COVID-19 vaccines in Nairobi's informal settings

13. Lines K, Sebbanja JA, Dzimadzi S, et al. Covid-19 Vaccine Rollout: Challenges and Insights from Informal Settlements. 2022;53(3). doi:10.1177/09562478221149876
14. Rothstein MA, Parmet WE, Reiss DR. Employer-Mandated Vaccination for COVID-19. *Am J Public Health*. 2021;111(6):1061-1064. doi:10.2105/AJPH.2020.306166
15. Diesel J, Sterrett N, Dasgupta S, et al. COVID-19 Vaccination Coverage Among Adults — United States, December 14, 2020–May 22, 2021. *Morb Mortal Wkly Rep*. 2021;70(25):922-927. doi:10.15585/mmwr.mm7025e1
16. Bhanu C, Gopal DP, Walters K, Chaudhry UAR. Vaccination uptake amongst older adults from minority ethnic backgrounds: A systematic review. *PLoS Med*. 2021;18(11):1-17. doi:10.1371/journal.pmed.1003826
17. Naranjo D, Kimball E, Nelson J, et al. Differences in perceptions and acceptance of COVID-19 vaccination between vaccine hesitant and non-hesitant persons. *PLoS One*. 2023;18(9 September):1-15. doi:10.1371/journal.pone.0290540
18. Lin Y, Hu Z, Zhao Q, Alias H, Danaee M, Wong LP. Understanding COVID-19 vaccine demand and hesitancy: A nationwide online survey in China. *PLoS Negl Trop Dis*. 2020;14(12):e0008961. doi:10.1371/journal.pntd.0008961
19. Roberts-McCarthy E, Buck PO, Smith-Ray RL, et al. Factors associated with receipt of mRNA-1273 vaccine at a United States national retail pharmacy during the COVID-19 pandemic. *Vaccines*. 2023;41(29):4257-4266. doi:10.1016/j.vaccine.2023.03.076
20. Osur J, Muinga E, Carter J, Kuria S, Hussein S, Ileri EM. COVID-19 vaccine hesitancy: Vaccination intention and attitudes of community health volunteers in Kenya. *PLOS Glob Public Heal*. 2022;2(3 March):1-19. doi:10.1371/journal.pgph.0000233
21. Biswas MR, Alzubaidi MS, Shah U, Abd-Alrazaq AA, Shah Z. A scoping review to find out worldwide covid-19 vaccine hesitancy and its underlying determinants. *Vaccines*. 2021;9(11):1-20. doi:10.3390/vaccines9111243
22. Rukchart N, Hnuploy K, Eltaybani S, et al. Prevalence and determinants of COVID-19 vaccine acceptance among vulnerable populations in Thailand: An application of the health belief model. *Heliyon*. 2024;10(4):e26043. doi:10.1016/j.heliyon.2024.e26043
23. Stamm TA, Partheymüller J, Mosor E, et al. Determinants of COVID-19 vaccine fatigue. *Nat Med*. 2023;29(5):1164-1171. doi:10.1038/s41591-023-02282-y